Packer recently proposed an intriguing hypothesis that DPP-4 inhibitors potentiate some endogenous peptides, such as stromal cell-derived factor-1, in addition to activation of GLP-1, and that unfavorable effects of those peptides on CV parameters (e.g., inflammation, fibrosis, plaque growth, and sympathetic activation) could prevail against the CV protective effects of GLP-1, possibly leading to worsened CV complications and HF [36, 37]
Some big employers that originally covered the weight-loss drugs have pulled back
As you can probably guess, this is another reason low T can result in reduced muscle mass
Social buffering of posttraumatic stress disorder: Longitudinal effects and neural mediators
TRIUMPH-3 featured about 1,950 participants with obesity and cardiovascular disease
It necessitates a thorough discussion with your healthcare provider, weighing the benefits of weight loss against the risks and challenges of managing gastrointestinal distress